Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases
作者:Michael R. Michaelides、Arthur Kluge、Michael Patane、John H. Van Drie、Ce Wang、T. Matthew Hansen、Roberto M. Risi、Robert Mantei、Carmen Hertel、Kannan Karukurichi、Alexandre Nesterov、David McElligott、Peter de Vries、J. William Langston、Philip A. Cole、Ronen Marmorstein、Hong Liu、Loren Lasko、Kenneth D. Bromberg、Albert Lai、Edward A. Kesicki
DOI:10.1021/acsmedchemlett.7b00395
日期:2018.1.11
screening hit. Conformational restraint in the form of a spirocyclization followed by substitution with a urea led to a significant improvement in potency. Replacement of the hydantoin moiety with an oxazolidinedione followed by fluoro substitution led to A-485, which exhibits potent cell activity, low clearance, and high oral bioavailability.
p300 及其旁系同源 CBP 可以乙酰化组蛋白和其他蛋白质,并与许多以异常基因激活为特征的疾病有关,例如癌症。通过虚拟配体筛选和随后对独特的乙内酰脲筛选命中进行优化,已鉴定出一种新型、高选择性、口服生物可利用的组蛋白乙酰转移酶 (HAT) 域抑制剂。螺环化形式的构象限制,然后用尿素取代导致效力的显着提高。用恶唑烷二酮替换乙内酰脲部分,然后进行氟取代导致A-485,其表现出有效的细胞活性、低清除率和高口服生物利用度。